The Pros and Cons of Diagnosing Diabetes With A1C

An International Expert Committee was convened in 2008 by the American Diabetes Association (ADA), the European Association for the Study of Diabetes, and the International Diabetes Federation to consider the means for diagnosing diabetes in nonpregnant individuals, with particular focus on the possibility to indicate A1C as an alternative if not a better tool (1). After reviewing the available literature and a thorough discussion on the advantages and the limits of previous diagnostic strategies (essentially based on fasting glucose assessment) and the considered alternative approach (based on A1C measurement), a consensus was reached that the latter (i.e., A1C) should be included among diagnostic tools for diabetes and, with the exception of a number of clinical conditions, should even be preferred in diabetes diagnosis in nonpregnant adults. The main conclusion of the International Expert Committee was implemented in the most recent clinical recommendations issued by the ADA. However, in these guidelines, A1C is indicated as a diagnostic tool alternative but not superior to blood glucose, leaving to the health care professional the decision about what test to use in an individual. The World Health Organization is currently examining the proposal made by the International Expert Committee and is carefully addressing the controversial issues still remaining, most of which have been the subject of letters to the editor and articles recently published in the literature. Nevertheless, the use of A1C for diagnosing diabetes is rapidly becoming a reality in many Western countries. In the text that follows, one of us (E.B.) will present the main points supporting A1C (pros) and the other (J.T.) will illustrate the main counterpoints challenging A1C (cons) as the primary tool for diabetes diagnosis. The text has been prepared in full coordination and the final conclusions represent the opinion of both authors. Tables 1 and 2 summarize the …

[1]  J. Tuomilehto,et al.  Two prospective studies found that elevated 2-hr glucose predicted male mortality independent of fasting glucose and HbA1c. , 2004, Journal of clinical epidemiology.

[2]  Lei Zhang,et al.  Performance of an A1C and Fasting Capillary Blood Glucose Test for Screening Newly Diagnosed Diabetes and Pre-Diabetes Defined by an Oral Glucose Tolerance Test in Qingdao, China , 2009, Diabetes Care.

[3]  J. Shaw,et al.  Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study , 2009, Diabetologia.

[4]  K. Reynolds,et al.  Comparison of A1C and Fasting Glucose Criteria to Diagnose Diabetes Among U.S. Adults , 2009, Diabetes Care.

[5]  E. Feskens,et al.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.

[6]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[7]  K. Eriksson,et al.  No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise , 1998, Diabetologia.

[8]  S. Yusuf,et al.  Diagnostic strategies to detect glucose intolerance in a multiethnic population. , 2003, Diabetes care.

[9]  J. Tuomilehto,et al.  Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[10]  R. Little,et al.  Biological variation of glycohemoglobin. , 2002, Clinical chemistry.

[11]  B. Davies,et al.  European Association for the Study of Diabetes , 1984 .

[12]  E. Ford,et al.  Prevalence of Diabetes and High Risk for Diabetes Using A1C Criteria in the U.S. Population in 1988–2006 , 2010, Diabetes Care.

[13]  R. Hanson,et al.  Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes , 1994, BMJ.

[14]  John M. Lachin,et al.  Differences in A1C by Race and Ethnicity Among Patients With Impaired Glucose Tolerance in the Diabetes Prevention Program , 2007 .

[15]  Mathias M. Müller,et al.  Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement , 2007, Diabetes Care.

[16]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[17]  V. Mohan,et al.  Moving to an A1C-Based Diagnosis of Diabetes Has a Different Impact on Prevalence in Different Ethnic Groups , 2009, Diabetes Care.

[18]  M. Rewers,et al.  A1C Between 5.7 and 6.4% as a Marker for Identifying Pre-Diabetes, Insulin Sensitivity and Secretion, and Cardiovascular Risk Factors , 2010, Diabetes Care.

[19]  D. Bruns,et al.  Stabilization of glucose in blood specimens: mechanism of delay in fluoride inhibition of glycolysis. , 2008, Clinical chemistry.

[20]  T. Valle,et al.  Ten-Year Mortality and Cardiovascular Morbidity in the Finnish Diabetes Prevention Study—Secondary Analysis of the Randomized Trial , 2009, PloS one.

[21]  J. Eriksson,et al.  HbA1c in diagnosing and predicting Type 2 diabetes in impaired glucose tolerance: the Finnish Diabetes Prevention Study , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[22]  D. Katritsis,et al.  Measurement of glycated hemoglobin (HbA1c) with an automated POCT instrument in comparison with HPLC and automated immunochemistry method: evaluation of the influence of hemoglobin variants , 2006, Clinical chemistry and laboratory medicine.

[23]  J. Shaw,et al.  International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes , 2009, Diabetes Care.

[24]  David E Bruns,et al.  Stabilization of glucose in blood samples: why it matters. , 2009, Clinical chemistry.

[25]  Timothy M Reynolds,et al.  Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. , 2004, Diabetes care.

[26]  L. Groop,et al.  The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes , 2010, Diabetes/metabolism research and reviews.

[27]  Lothar Siekmann,et al.  State of the art in trueness and interlaboratory harmonization for 10 analytes in general clinical chemistry. , 2008, Archives of pathology & laboratory medicine.

[28]  M. Hanefeld,et al.  Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up , 1996, Diabetologia.

[29]  G. Bicescu Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. , 2010, Maedica.

[30]  V. Mohan,et al.  A1C Cut Points to Define Various Glucose Intolerance Groups in Asian Indians , 2009, Diabetes Care.

[31]  L. Bouter,et al.  Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study , 1999, Diabetologia.

[32]  Ciprian M Crainiceanu,et al.  Short-term variability in measures of glycemia and implications for the classification of diabetes. , 2007, Archives of internal medicine.

[33]  A. Karter,et al.  Hemoglobin A 1 c between 5 . 7 and 6 . 4 % as a marker for identifying prediabetes , insulin sensitivity and secretion , and cardiovascular risk factors : The Insulin Resistance Atherosclerosis Study ( IRAS ) , 2010 .

[34]  M. Engelgau,et al.  Comparison of Fasting and 2-Hour Glucose and HbA1c Levels for Diagnosing Diabetes: Diagnostic criteria and performance revisited , 1997, Diabetes Care.

[35]  N. Day,et al.  Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk , 2004, Annals of Internal Medicine.